SK pharmteco News and Resources

SK pharmteco, a global contract development and manufacturing organisation (CDMO), has expanded its stability storage capabilities at its El Dorado Hills site in California. The new validated chambers increase storage capacity by 40% and are designed to meet rising demand

SK pharmteco, a global contract development and manufacturing organization (CDMO), has announced the launch of a new CGMP plasmid suite at its King of Prussia, Pennsylvania facility. The expansion is aimed at increasing the supply of high-quality plasmids used in

SK pharmteco has embarked on a key sustainability initiative by pursuing My Green Lab Certification, a globally recognized standard for laboratory sustainability. The company completed its baseline assessment in late 2024 and is targeting its first certification milestone by mid-2025, with

SK pharmteco, a global contract development and manufacturing organisation (CDMO), has announced the expansion of its capabilities with the launch of a specialised analytical testing laboratory dedicated to High Potency Active Pharmaceutical Ingredients (HPAPIs). The facility, located at the company’s

SK pharmteco, a global contract development, manufacturing, and analytical testing organization serving the pharmaceutical and cell & gene therapy industries, has unveiled a brand unification strategy, consolidating its worldwide operations under a single name. The initiative merges the capabilities of

SK pharmteco, a global contract development and manufacturing organisation (CDMO), has announced a multi-year agreement with biotechnology firm AaviGen GmbH. The agreement appoints SK pharmteco as the preferred manufacturing partner for AaviGen’s lead gene therapy product AVG-101, aimed at treating

SK pharmteco, a global contract development and manufacturing organization (CDMO), has announced a $260 million investment to expand its small molecule and peptide production capabilities. The new facility will be located in Sejong, South Korea, and is scheduled to begin

Cryoport, Inc. and SK pharmteco have entered a strategic collaboration to provide integrated logistics and manufacturing services to biotechnology and pharmaceutical companies. This partnership combines Cryoport’s expertise in supply chain solutions with SK pharmteco’s contract manufacturing capabilities, creating a streamlined

SK pharmteco, a global contract development, manufacturing, and analytical testing organization, has signed a memorandum of understanding (MOU) with South Korea-based biopharmaceutical company Rznomics Inc. The agreement establishes a multi-year strategic partnership focused on developing and commercializing RNA-based gene therapies.